Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Sleep Onset Latency
Interventions: Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs; Device
Lead sponsor: University of Arizona; Other
Eligibility: 60 Months to 83 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Opioid Dependence, Methadone Withdrawal Syndrome
Interventions: Lofexidine HCl, Lofexidine-matching sugar pill; Drug
Lead sponsor: USWM, LLC (dba US WorldMeds); Industry
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Geographic Atrophy of the Macula
Interventions: GAL-101, Placebo; Drug
Lead sponsor: Galimedix Therapeutics Inc; Industry
Eligibility: 55 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland

Conditions: Alzheimer's Disease
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS), NICE Cognitive Training; Device · Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 55 Years to 90 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Otomycosis
Interventions: miconazole 2% oil, vehicle oil; Drug
Lead sponsor: Hill Dermaceuticals, Inc.; Industry
Eligibility: 7 Years and older
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Chula Vista, California • La Jolla, California • Roseville, California + 9 more

Conditions: Elevated Triglycerides, Cardiovascular Risk Factor
Interventions: DPA enriched n-3, n-3 control, Placebo; Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Melanoma
Interventions: Epacadostat, ipilimumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 7
States / cities: Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more

Conditions: N/A Healthy Individuals
Interventions: Myofascial Release, Light Touch Contact; Other
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: Acute Schizophrenia
Interventions: Brexpiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Anaheim, California • Cerritos, California • Garden Grove, California + 10 more

Conditions: Hereditary Angioedema
Interventions: Donidalorsen, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Scottsdale, Arizona • San Diego, California • Santa Monica, California + 12 more

Conditions: COVID-19
Interventions: PF-07321332, Ritonavir, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 78
States / cities: Pelham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more

Conditions: Alcoholism, Cocaine Dependence
Interventions: Naltrexone, BRENDA, CBT, Placebo; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Interventions: AG10, Placebo; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Povorcitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 37
States / cities: Phoenix, Arizona • Arkansas City, Arkansas • Fort Smith, Arkansas + 32 more

Conditions: Plaque Psoriasis
Interventions: Ixekizumab, Guselkumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,027 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 98
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 82 more

Conditions: Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions: IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg; Drug
Lead sponsor: Idera Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 13
States / cities: Jacksonville, Florida • Alpharetta, Georgia • Macon, Georgia + 9 more

Conditions: Acute Ischemic Stroke
Interventions: natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 13 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin plus metformin IR, Placebo plus metformin IR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 25
States / cities: Concord, California • Fountain Valley, California • Lomita, California + 22 more

Conditions: Constipation
Interventions: MD-1100 Acetate; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 14
States / cities: Huntsville, Alabama • North Little Rock, Arkansas • Boynton Beach, Florida + 11 more

Conditions: Ulcerative Colitis, Active Moderate
Interventions: Fecal Microbiota Transplant, Placebo; Biological
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Sunphenon, Placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Westwood, Kansas

Conditions: Pain, Postoperative
Interventions: Active Comparator, Placebo Comparator; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Body Weight
Interventions: Weight Management Formulation, Placebo, Handout with Suggestions for Healthy Eating and Overall Health; Dietary Supplement · Other
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Coronary Disease
Interventions: placebo, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Clearwater, Florida

Search by objective public record fields.

Circadian Light Exposure Adjustment for Restfulness

Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients

Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)

Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Does Manual Therapy Provide Immediate Improvement in Lumbar Range of Motion?

Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Participants With Hereditary Angioedema (HAE)

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus

Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation

Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

Quadratus Lumborum Block for Total Hip Arthroplasty

Study to Evaluate the Effects of a Weight Management Program on Body Weight

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome